F232. A PHASE 3 STUDY TO DETERMINE THE ANTIPSYCHOTIC EFFICACY AND SAFETY OF ALKS 3831 IN ADULT PATIENTS WITH ACUTE EXACERBATION OF SCHIZOPHRENIA

BACKGROUND: ALKS 3831, currently under development for the treatment of schizophrenia, is composed of a flexible dose of olanzapine (OLZ) and a fixed dose of 10 mg of samidorphan. In a Phase 2 study, ALKS 3831 mitigated OLZ-associated weight gain and exhibited antipsychotic efficacy similar to OLZ a...

Descripción completa

Detalles Bibliográficos
Autores principales: McDonnell, David, Potkin, Steven G, Simmons, Adam, Jiang, Ying, DiPetrillo, Lauren, Silverman, Bernard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888656/
http://dx.doi.org/10.1093/schbul/sby017.763

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888656/
http://dx.doi.org/10.1093/schbul/sby017.763

Ejemplares similares